NovaBay Pharmaceuticals Secures $6 Million Investment from David E. Lazar, Appoints New CEO

NovaBay Pharmaceuticals has entered into a $6 million securities purchase agreement with private investor David E. Lazar. The deal includes a first closing of $3.85 million, with a second closing contingent on stockholder approval. Lazar has been appointed CEO and a director of NovaBay, and the company intends to use the proceeds to pursue a strategic investment and/or acquisition. A special cash dividend is expected during Q3 2025.